Oncologic Emergency A to Z : 腫瘍緊急を知る

出版社： へるす出版
著者：
発行日： 2023-09-08
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784867190753
電子書籍版： 2023-09-08 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

がんとその治療にかかわる症状と病態――“腫瘍緊急（oncologic emergency）”に焦点を当てた、本邦初の“腫瘍緊急”本がついに完成。分野を横断した医療者たちの知見が集約され、これまで分野別に切り離されて示されることの多かった腫瘍緊急が、初めてその全体像を表す。「2人に1人ががんに罹患する」といわれている本邦において、腫瘍緊急対応は喫緊の課題である。がん診療に携わるすべての医療者の皆様の役に立つ、今まさに必要な一冊。

目次

  • 第１章　総論
    　はじめに
    　腫瘍緊急（OE）とは
    　病態と分類
    　代表的な腫瘍緊急（OE）
    　おわりに

    第２章　消化器腫瘍外科の立場から
    　1　上部・下部消化管
    　　　はじめに
    　　　食道疾患
    　　　胃疾患
    　　　大腸疾患
    　　　おわりに
    　2　肝・胆・膵
    　　　はじめに
    　　　肝細胞がん（HCC）破裂の概要
    　　　肝細胞がん（HCC）破裂の治療
    　　　おわりに

    第３章　呼吸器腫瘍外科の立場から
    　はじめに
    　気道狭窄
    　上大静脈症候群（SVCS）
    　喀血
    　がん性胸膜炎
    　がん性心膜炎
    　おわりに

    第４章　薬物療法専門医の立場から
    　薬物療法専門医の立場からみた腫瘍緊急（OE）
    　上大静脈症候群（SVCS）
    　気道狭窄
    　電解質異常
    　脊髄圧迫
    　消化器系の腫瘍緊急（OE）
    　泌尿器系の腫瘍緊急（OE）
    　腫瘍崩壊症候群（TLS）
    　発熱性好中球減少症（FN）
    　静脈血栓塞栓症（VTE）
    　播種性血管内凝固症候群（DIC）
    　おわりに

    第５章　脳神経外科の立場から
    　はじめに
    　頭蓋内圧亢進
    　脳ヘルニア
    　脳腫瘍に関連した腫瘤効果（mass effect）
    　血管に関連する合併症
    　腫瘍性てんかん
    　てんかん重積状態
    　内分泌関連合併症
    　髄膜がん腫症（LM）
    　治療関連合併症
    　おわりに

    第６章　血液腫瘍科の立場から
    　はじめに
    　血球増多による腫瘍緊急（OE）
    　血球減少による腫瘍緊急（OE）
    　凝固異常による腫瘍緊急（OE）
    　その他の造血器腫瘍による腫瘍緊急（OE）
    　おわりに

    第７章　泌尿器科の立場から
    　はじめに
    　尿路出血
    　尿路閉塞
    　おわりに

    第８章　がん免疫療法の立場から
    　はじめに
    　免疫関連有害事象（irAE）
    　マネジメント
    　サイトカイン放出症候群（CRS）
    　急速な腫瘍増大（HPD）の概要
    　おわりに

    第９章　緩和ケアの立場から
    　はじめに
    　緩和ケアの概念，歴史的変遷
    　腫瘍緊急（OE）と緩和ケアの接点
    　人生会議（ACP）
    　DNR の概念
    “ボタンの掛け違い”の防止対策
    　緩和ケアチームが遭遇する腫瘍緊急（OE）
    　生命予後の予測
    　緩和ケアにおける鎮静
    　おわりに

    第10章　救急医の立場から
    　はじめに
    　今後，腫瘍緊急（OE）に向き合う救急シーンが激増する
    　悪性腫瘍（がん）そのものによって引き起こされる緊急病態
    　がん治療によって引き起こされる緊急病態
    　急性疼痛クライシス
    　救急診療で直面するend‒of‒life care
    　おわりに

    第11章　在宅医療の立場から
    　社会の高齢化；本邦の医療の特殊性
    　本邦の在宅医療
    　がんと在宅医療
    　在宅医療における腫瘍緊急（OE）の課題と現状
    　症例
    　おわりに

    第12章　麻酔科の立場から
    　はじめに
    　がんの再発・増殖と周術期管理
    　腫瘍随伴症候群に対する麻酔の対応
    　がんによる構造的なものや化学療法，放射線療法による合併症
    　分子標的療法と麻酔管理
    　おわりに

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 総論

P.10 掲載の参考文献
1) 鈴木梢, 武居哲洋, 伊藤敏孝, 他:救急外来受診を契機に診断されたがん症例の検討. 日救急医会誌 2010;21:779-85.
 
2) Memorial Sloan Kettering Cancer Center:About the Urgent Care Center at Memorial Sloan Kettering. https://www.mskcc.org/cancer-care/patient-education/urgent-care-center
 
3) Alagappan K:Emergency Medicine. MD Anderson Cancer Center. http://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/emergency-medicine.html
 
4) がん研有明病院:診療科・部門紹介;救急部. https://www.jfcr.or.jp/hospital/department/clinic/central/emergency/feature.html
 
5) 日本赤十字社和歌山医療センター:がん救急. https://www.wakayama-med.jrc.or.jp/gan_center/treatment/cancerqq.html
 
6) Thandra K, Salah Z, Chawla S:Oncologic emergencies for the intensivist:The old, the new, and the deadly. J Intensive Care Med 2020;35:3-13.
PubMed
7) Gould Rothberg BE, Quest TE, Yeung SJ, et al:Oncologic emergencies and urgencies:A comprehensive review. CA Cancer J Clin 2022;72:570-93.
PubMed
8) Higdon ML, Atkinson CJ, Lawrence KV:Oncologic emergencies:Recognition and initial management. Am Fam Physician 2018;97:741-8.
PubMed
9) Rosenberg PS, Alter BP, Bolyard AA, et al:The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006;107:4628-35.
PubMed
10) Wisplinghoff H, Seifert H, Wenzel RP, et al:Current trends in the epidemiology of nosocomical bloodstream infections in patients with hematological malignancies and solid neoplasm in hospital in the United States. Clin Infect Dis 2003;36:1103-10.
 
11) Freifeld AG, Bow EJ, Sepkowitz KA, et al:Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93.
 
12) Klastersky J, Paesmans M, Rubenstein EB, et al:The Multinational Association for Supportive Care in Cancer risk index:A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
PubMed
13) Carmona-Bayonas A, Jimenes-Fonseca P, Virinzuela Echaburu J, et al:Prediction of serious complications in patients with seemingly stable febrile neutropenia:Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patient from the FINITE study. J Clin Oncol 2015;33:465-71.
 
14) Belay Y, Yirdaw K, Enawgaw B:Tumor lysis syndrome in patients with hematological malignancies. J Oncol 2017;2017:9684909.
PubMed
15) Mirrakhimov AE, Voore P, Khan M, et al:Tumor lysis syndrome:A clinical review. World J Crit Care Med 2015;4:130.
PubMed
16) Wilson FP, Berns JS:Tumor lysis syndrome:New challenges and recent advances. Adv Chronic Kidney Dis 2014;21:18-26.
PubMed
17) Cairo MS, Coiffier B, Reiter A, et al:Recommendations for the evaluation of risk and prophylaxia of tumor lysis syndrome (TLS) in adults and children with malignant diseases:An expert TLS panel consensus. Br J Haematol 2010;149:578-86.
 
18) Coiffier B, Altman A, Pui CH, et al:Guidelines for the management of pediatric and adult tumor lysis syndrome:An evidence-based review. J Clin Oncol 2008;20:2767-78.
 
19) 田島健:肺癌において腫瘍随伴症候群の鑑別は重要である. 内科 2021;128:369-72.
 
20) Pelosof IC, Gerber DE:Paraneoplastic syndrome:An approach to diagnosis and treatment. Mayo Clin Proc 2010;85:838-54.
 
21) Sodergren SC, White A, Efficace F, et al:Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 2014;91:35-46.
 
22) Morris EC, Neelapu SS, Giavridis T, et al:Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022;22:85-96.
PubMed
23) Fajgenbaum DC, June CH:Cytokine storm. N Engl J Med 2020;383:2255-73.
PubMed
24) Long B, Brem E, Koyfman A:Oncologic emergencies:Immune-based cancer therapies and complications. Western J Emrg Med 2020;21:566-80.
 

第2章 消化器腫瘍外科の立場から

P.16 掲載の参考文献
1) Marone EM, Coppi G, Kahlberg A, et al:Combined endovascular and surgical treatment of primary aortoesophageal fistula. Tex Heart Inst J 2010;37:722-4.
PubMed
2) Watanabe M, Nakajima M, Nishikawa K, et al:Thoracic endovascular aortic repair for esophageal cancer invading the thoracic aorta:A questionnaire survey study. Esophagus 2020;17:74-80.
PubMed
3) 中原裕次郎, 高地耕, 辻村直人, 他:食道および気道ステントを留置した進行食道癌8例の治療成績. 癌と化学療法 2017;44:1161-3.
Medical*Online
4) 生山裕一, 安尾将法, 曽根原圭, 他:原発不明癌による食道狭窄, 気管食道瘻に対し気管ステント, 食道ステントを留置し, 経口摂取が可能となった1例. 気管支学 2020;42:188-92.
Medical*Online
5) 荒井邦佳, 北村正次, 岩崎善毅:空置的胃空腸吻合術. 手術 1998;52:1135-41.
 
6) 辻本広紀, 小野聡, 平木修一, 他:胃癌穿孔例の臨床病理学的特徴と予後. 日腹部救急医会誌 2010;30:647-50.
 
7) 三原大樹, 赤井正明, 高木章司, 他:胃穿孔を契機に発見された胃癌に対する治療成績の検討. 岡山赤十字病医誌 2022;33:62-5.
 
8) Hata T, Sakata N, Kudoh K, et al:The best surgical approach for perforated gastric cancer:One-stage vs. two-stage gastrectomy. Gastric Cancer 2014;17:578-87.
PubMed
9) 増田貴史, 堀場昌英, 芳賀孝之, 他:両肺の癌性リンパ管症を初発症状とした進行胃癌の1例. 日呼吸誌 2014;3:599-602.
 
10) 大江裕一郎:癌性リンパ管症の診かた. 治療 2003;85:1942-6.
Medical*Online
11) 佐藤隆, 松原修, 春日盂:肺の癌性リンパ管症の臨床病理学的検討;その発生と進展様式. 日本胸部疾患学会雑誌 1988;26:1243-8.
 
12) 遠藤久仁, 大谷聡, 高間朗, 他:イマチニブ投与中に腹腔内出血を来したgastrointestinal stromal tumor腹膜播種症例に外科的切除を施行し, イマチニブ投与を継続しえた2例. 日消外会誌 2014;47:616-22.
 
13) Demetri GD, von Mehren M, Blanke CD, et al:Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
PubMed
14) 松本顕佑, 小林正美, 武田洋平, 他:腹腔内出血をきたした胃GISTに対し動脈塞栓術を施行した1例. 臨床放射線 2015;60:577-81.
 
15) Yeo HL, Lee SW:Colorectal emergencies:Review and controversies in the management of large bowel obstruction. J Gastrointest Surg 2013;17:2007-12.
PubMed
16) Tekkis PP, Kinsman R, Thompson MR, et al:The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer. Ann Surg 2004;240:76-81.
PubMed
17) 小川真平, 板橋道朗, 井上雄志, 他:大腸癌術前減圧チューブ(イレウス管)による減圧療法のup-to-date. 日本大腸肛門病会誌 2020;73:404-9.
 
18) 成井一隆, 池秀之, 窪田徹, 他:穿孔により汎発性腹膜炎を起こした大腸癌の検討. 日腹部救急医会誌 2010;30:793-7.
 
19) 渋谷雅常, 寺岡均, 中尾重富, 他:大腸癌穿孔症例の臨床的検討. 日臨外会誌 2009;70:2276-80.
 
20) Saze Z, Miyata H, Konno H, et al:Risk models of operative morbidities in 16,930 critically ill surgical patients based on a Japanese nationwide database. Medicine (Baltimore) 2015;94:e1224.
PubMed
P.24 掲載の参考文献
1) 日本肝臓学会(編):肝がん白書 令和4年度. 2022. https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/liver_cancer_2022.pdf
 
2) 日本肝癌研究会肝癌追跡調査委員会(編):第24回全国原発性肝癌追跡調査報告(2016-2017). 日本肝癌研究会.
 
3) Sahu SK, Chawla YK, Dhiman RK, et al:Rupture of hepatocellular carcinoma:A review of literature. J Clin Exp Hepatol 2019;9:245-56.
PubMed
4) Zhu LX, Wang GS, Fan ST:Spontaneous rupture of hepatocellular carcinoma. Br J Surg 1996;83:602-7.
PubMed
5) Lai EC, Lau WY:Spontaneous rupture of hepatocellular carcinoma:A systematic review. Arch Surg 2006;141:191-8.
PubMed
6) Obeidat AE, Wong LL:Spontaneous rupture of hepatocellular carcinoma:New insights. J Clin Exp Hepatol 2022;12:483-91.
PubMed
7) Aoki T, Kokudo N, Matsuyama Y, et al:Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma:An analysis of 1,160 cases from a nationwide survey. Ann Surg 2014;259:532-42.
 
8) Xia F, Ndhlovu E, Zhang M, et al:Ruptured hepatocellular carcinoma:Current status of research. Front Oncol 2022;12:848903.
PubMed
9) 井上潤一, 大友康裕:REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta). 日外会誌 2019;120:282-9.
 
10) Okada H, Koike Y, Kishimoto S, et al:Successful management of resuscitative endovascular balloon occlusion of the aorta for hemorrhagic shock due to ruptured hepatocellular carcinoma. Intern Med 2022;61:1157-62.
PubMed
11) Hirai K, Kawazoe Y, Yamashita K, et al:Transcatheter arterial embolization for spontaneous rupture of hepatocellular carcinoma. Am J Gastroenterol 1986;81:275-9.
PubMed
12) Abikhaled JA, Granchi TS, Wall MJ, et al:Prolonged abdominal packing for trauma is associated with increased morbidity and mortality. Am Surg 1997;63:1109-12.
PubMed
13) Lee HS, Choi GH, Choi JS, et al:Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture:A multicenter analysis in Korea. Ann Surg Treat Res 2019;96:275-82.
PubMed
14) Tanaka S, Kaibori M, Ueno M, et al:Surgical outcomes for the ruptured hepatocellular carcinoma:Multicenter analysis with a case-controlled study. J Gastrointest Surg 2016;20:2021-34.
PubMed

第3章 呼吸器腫瘍外科の立場から

P.32 掲載の参考文献
1) Bosscher MR, van Leeuwen BL, Hoekstra HJ:Current management of surgical oncologic emergencies. PLoS One 2015;10:e0124641.
PubMed
2) Seijo LM, Sterman DH:Interventional pulmonology. N Engl J Med 2001;344:740-9.
PubMed
3) Guibert N, Saka H, Dutau H:Airway stenting:Technological advancements and its role in interventional pulmonology. Respirology 2020;25:953-62.
PubMed
4) Yu JB, Wilson LD, Detterbeck FC:Superior vena cava syndrome;A proposed classification system and algorithm for management. J Thorac Oncol 2008;3:811-4.
PubMed
5) 日本肺癌学会(編):肺癌診療ガイドライン;悪性胸膜中皮腫・胸腺腫瘍含む2022年版. 金原出版, 東京, 2022.
 
6) Kunitoh H, Tamura T, Shibata T, et al:A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 2009;100:464-9.
 

第4章 薬物療法専門医の立場から

P.42 掲載の参考文献
1) 日本臨床腫瘍学会(編):新臨床腫瘍学;がん薬物療法専門医のために. 改訂第5版, 南江堂, 東京, 2018.
 
2) 日本臨床腫瘍学会(編):新臨床腫瘍学;がん薬物療法専門医のために. 改訂第6版, 南江堂, 東京, 2021.
 
3) Rice TW, Rodriguez RM, Light RW:The superior vena cava syndrome:Clinical characteristics and evolving etiology. Medicine (Baltimore) 2006;85:37-42.
PubMed
4) Stewart AF:Clinical practice:Hypercalcemia associated with cancer. N Engl J Med 2005;352:373-9.
PubMed
5) Carano A, Teitelbaum SL, Konsek JD, et al:Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-61.
PubMed
6) Spasovski G, Vanholder R, Allolio B, et al:Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014;Suppl 2:i1-i39. https://academic.oup.com/ndt/article-abstract/29/suppl_2/i1/1904943
 
7) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):バソプレシン分泌過剰症(SIADH)の診断と治療の手引き(平成30年度改訂). 間脳下垂体機能障害の診断と治療の手引き(平成30年度改訂), 日内分泌会誌 2019;95(S. May):1-60.
 
8) Loblaw DA, Laperriere NJ, Mackillop WJ:A population-based study of malignant spinal cord compression in Ontario. Clin Oncol (R Coll Radiol) 2003;15:211-7.
PubMed
9) Ropper AE, Ropper AH:Acute spinal cord compression. N Engl J Med 2017;376:1358-69.
PubMed
10) Patchell RA, Tibbs PA, Regine WF, et al:Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer:A randomised trial. Lancet 2005;366:643-8.
PubMed
11) 日本臨床腫瘍学会(編):腫瘍崩壊症候群(TLS)診療ガイダンス. 第2版, 金原出版, 東京, 2021.
 
12) Gemici C:Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 2006;18:773-80.
PubMed
13) 日本臨床腫瘍学会(編):発熱性好中球減少症(FN)診療ガイドライン;がん薬物療法時の感染対策. 改訂第2版, 南江堂, 東京, 2017.
 
14) Klastersky J, Paesmans M, Rubenstein EB, et al:The Multinational Association for Supportive Care in Cancer risk index:A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
PubMed
15) Young AM, Marshall A, Thirlwall J, et al:Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism:Results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017-23.
 
16) Raskob GE, van Es N, Verhamme P, et al:Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24.
PubMed
17) Agnelli G, Becattini C, Meyer G, et al:Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607.
PubMed
18) 日本血栓止血学会学術標準化委員会DIC部会:科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 2009;20:77-113.
 

第5章 脳神経外科の立場から

P.65 掲載の参考文献
1) Sizoo EM, Braam L, Postma TJ, et al:Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 2010;12:1162-6.
PubMed
2) Riveros Gilardi B, Munoz Lopez JI, Hernandez Villegas AC, et al:Types of cerebral herniation and their imaging features. Radiographics 2019;39:1598-610.
PubMed
3) Deangelis LM, Hormigo A:Treatment of primary central nervous system lymphoma. Semin Oncol 2004;31:684-92.
PubMed
4) Weller M:Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999;43:237-9.
PubMed
5) Haldorsen IS, Espeland A, Larsen JL, et al:Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 2005;44:728-34.
PubMed
6) Bullis CL, Maldonado-Perez A, Bowden SG, et al:Diagnostic impact of preoperative corticosteroids in primary central nervous system lymphoma. J Clin Neurosci 2020;72:287-91.
PubMed
7) Binnahil M, Au K, Lu JQ, et al:The influence of corticosteroids on diagnostic accuracy of biopsy for primary central nervous system lymphoma. Can J Neurol Sci 2016;43:721-5.
PubMed
8) Kreisl TN, Toothaker T, Karimi S, et al:Ischemic stroke in patients with primary brain tumors. Neurology 2008;70:2314-20.
PubMed
9) Cote DJ, Smith TR:Venous thromboembolism in brain tumor patients. J Clin Neurosci 2016;25:13-8.
PubMed
10) Gerber DE, Grossman SA, Streiff MB:Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006;24:1310-8.
PubMed
11) Cestari DM, Weine DM, Panageas KS, et al:Stroke in patients with cancer:Incidence and etiology. Neurology 2004;62:2025-30.
PubMed
12) Seidel C, Hentschel B, Simon M, et al:A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol 2013;260:847-55.
 
13) Kamiya-Matsuoka C, Cachia D, Yust-Katz S, et al:Ischemic stroke in patients with gliomas at The University of Texas-M. D. Anderson Cancer Center. J Neurooncol 2015;125:143-8.
 
14) Roth P, Pace A, Le Rhun E, et al:Neurological and vascular complications of primary and secondary brain tumours:EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol 2021;32:171-82.
PubMed
15) Tsivgoulis G, Safouris A, Alexandrov AV:Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions. Expert Opin Drug Saf 2015;14:845-64.
PubMed
16) Cestari DM, Weine DM, Panageas KS, et al:Stroke in patients with cancer:Incidence and etiology. Neurology 2004;62:2025-30.
PubMed
17) Zukas AM, Bennani NN, Chou CZ, et al:Intravascular lymphoma affecting the central nervous system:Features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 2016;18:iv168.
 
18) Lin RJ, Green DL, Shah GL:Therapeutic anticoagulation in patients with primary brain tumors or secondary brain metastasis. Oncologist 2018;23:468-73.
PubMed
19) Lee AY, Levine MN, Baker RI, et al:Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
PubMed
20) Levin JM, Schiff D, Loeffler JS, et al:Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993;43:1111-4.
PubMed
21) Nalluri SR, Chu D, Keresztes R, et al:Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:A meta-analysis. JAMA 2008;300:2277-85.
PubMed
22) Chinot OL, Wick W, Mason W, et al:Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
PubMed
23) Gilbert MR, Sulman EP, Mehta MP:Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:2048-9.
PubMed
24) Wick W, Gorlia T, Bendszus M, et al:Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 2017;377:1954-63.
PubMed
25) Katz JM, Segal AZ:Incidence and etiology of cerebrovascular disease in patients with malignancy. Curr Atheroscler Rep 2005;7:280-8.
PubMed
26) Linn J, Bruckmann H:Differential diagnosis of nontraumatic intracerebral hemorrhage. Klin Neuroradiol 2009;19:45-61.
 
27) Boissonneau S, Graillon T, Rolland A, et al:Dufour management of patients suffering from hemorrhagic intracranial metastases:Propositions to help the neurosurgeon in emergency situations based on a literature review. Neurochirurgie 2021;67:369-74.
PubMed
28) Schrader B, Barth H, Lang EW, et al:Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir 2000;142:979-85.
PubMed
29) Chang L, Chen Y-LL, Kao M-CC:Intracranial metastasis of hepatocellular carcinoma:Review of 45 cases. Surg Neurol 2004;62:172-7.
 
30) Wronski M, Arbit E, Russo P, et al:Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996;47:187-93.
PubMed
31) Byrne TN, Cascino TL, Posner JB:Brain metastasis from melanoma. J Neurooncol 1983;1:313-7.
PubMed
32) Wang D, Shu H, Zhang Q, et al:Brain metastasis of choriocarcinoma presenting as multiple intracranial hematomas:A case report. Medicine (Baltimore) 2018;97:e12275.
 
33) Macdonald RL:Management of intracanial hemorrhage in the anticoagulated patient. Neurosurg Clin N Am 2018;29:605-13.
 
34) Marenco-Hillembrand L, Suarez-Meade P, Ruiz Garcia H, et al:Minimally invasive surgery and transsulcal parafascicular approach in the evacuation of intracerebral haemorrhage. Stroke Vasc Neurol 2019;5:40-9.
PubMed
35) Nguyen TD, Abrey LE:Brain metastases:Old problem, new strategies. Hematol Oncol Clin North Am 2007;21:369-88.
PubMed
36) Mantia C, Uhlmann EJ, Puligandla M, et al:Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 2017;129:3379-85.
PubMed
37) Chang SM, Messersmith H, Vogelbaum MA:Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors:ASCO/SNO Joint Endorsement Summary of College of Neurologic Surgeons Guidelines. J Oncol Pract 15:395-7.
 
38) Han S, Yang Y, Yang Z, et al:Continuous progression of hemorrhage of sphenoid ridge meningioma causing cerebral hernia:A case report and literature review. Oncol Lett 2020;20:785-93.
 
39) Hambra DV, Danilo de P, Alessandro R, et al:Meningioma associated with acute subdural hematoma:A review of the literature. Surg Neurol Int 2014;5(suppl 12):S469-71.
 
40) Krishnan V, Mittal MK, Sinha M, et al:Imaging spectrum of meningiomas:A review of uncommon imaging appearances and their histopathological and prognostic significance. Pol J Radiol 2019;84:e630-53.
PubMed
41) Foster E, Carney P, Liew D, et al:First seizure in adults:Beyond assessment and treatment. J Neurol Neuro surg Psychiatry 2019;90:1039-45.
 
42) Pallud J, Audureau E, Blonski M, et al:Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137:449-62.
PubMed
43) Ruda R, Bello L, Duffau H, et al:Seizures in low-grade gliomas:Natural history, pathogenesis, and outcome after treatments. Neuro Oncol 2012;14 Suppl 4:iv55-64.
 
44) Van Breemen MS, Wilms EB, Vecht CJ:Epilepsy in patients with brain tumours:Epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421-30.
PubMed
45) Maschio M:Brain tumor-related epilepsy. Curr Neuropharmacol 2012;10:124-33.
PubMed
46) Lee JW, Wen PY, Hurwitz S, et al:Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010;67:336-42.
PubMed
47) Chen DY, Chen CC, Crawford JR, et al:Tumor-related epilepsy:Epidemiology, pathogenesis and management. J Neurooncol 2018;139:13-21.
PubMed
48) Englot DJ, Chang EF:Rates and predictors of seizure freedom in resective epilepsy surgery:An update. Neurosurg Rev 2014;37:389-404.
PubMed
49) Glauser T, Ben-Menachem E, Bourgeois B, et al:Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63.
PubMed
50) Maschio M, Aguglia U, Avanzini G, et al:Management of epilepsy in brain tumors. Neurol Sci 2019;40:2217-34.
PubMed
51) Nasr ZG, Paravattil B, Wilby KJ:Levetiracetam for seizure prevention in brain tumor patients:A systematic review. J Neurooncol 2016;129:1-13.
PubMed
52) Rosati A, Buttolo L, Stefini R, et al:Efficacy and safety of levetiracetam in patients with glioma:A clinical prospective study. Arch Neurol 2010;67:343-6.
PubMed
53) Goonawardena J, Marshman LA, Drummond KJ:Brain tumor-associated status epilepticus. J Clin Neurosci 2015;22:29-34.
PubMed
54) Claasen J, Lokin JK, Fitzsimmons BF, et al:Predictors of functional disability and mortality after status epilepticus. Neurology 2002;58:139-42.
 
55) DeLorenzo RJ, Pellock JM, Towne AR, et al:Epidemiology of status epilepticus. J Clin Neurophysiol 1995;12:316-25.
PubMed
56) Cocito L, Audeino D, Primavera A:Altered mental state and non-convulsive status epilepticus in patients with cancer. Arch Neurol 2001;58:1310.
 
57) Betjemann JP, Lowenstein DH:Status epilepticus in adults. Lancet Neurol 2015;14:615-24.
PubMed
58) Briet C, Salenave S, Bonneville JF, et al:Pituitary apoplexy. Endocr Rev 2015;36:622-45.
PubMed
59) Glezer A, Bronstein MD:Pituitary apoplexy:Pathophysiology, diagnosis and management. Arch Endocrinol Metab 2015;59:259-64.
PubMed
60) Briet C, Salenave S, Bonneville JF, et al:Pituitary apoplexy. Endocr Rev 2015;36:622-45.
PubMed
61) Semple PL, Jane JA, Lopes MB, et al:Pituitary apoplexy:Correlation between magnetic resonance imaging and histopathological results. J Neurosurg 2008;108:909-15.
PubMed
62) Boellis A, di Napoli A, Romano A, et al:Pituitary apoplexy:An update on clinical and imaging features. Insights Imaging 2014;5:753-62.
PubMed
63) Baldeweg SE, Vanderpump M, Drake W, et al:Society for Endocrinology Endocrine Emergency Guidance:Emergency management of pituitary apoplexy in adult patients. Endocr Connect 2016;5:G12-5.
PubMed
64) Fu W, Duan L, Geng S, et al:Surgical outcomes of cavernous sinus syndrome in pituitary adenomas world. Neurosurg 2017;107:526-33.
PubMed
65) Johnston PC, Hamrahian AH, Weil RJ, et al:Pituitary tumor apoplexy. J Clin Neurosci 2015;22:939-44.
PubMed
66) Chamberlain MC:Leptomeningeal metastasis. Curr Opin Oncol 2010;22:627-35.
PubMed
67) Groves MD:Leptomeningeal disease. Neurosurg Clin N Am 2011;22:67-78, vii.
PubMed
68) Glass JP, Melamed M, Chernik NL, et al:Malignant cells in cerebrospinal fluid (CSF):The meaning of a positive CSF cytology. Neurology 1979;29:1369-75.
PubMed
69) Clarke JL:Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn) 2012:18:328-42.
PubMed
70) Clarke JL, Perez HR, Jacks LM, et al:Leptomeningeal metastases in the MRI era. Neurology 2010;74:1449-54.
PubMed
71) Passarin MG, Sava T, Furlanetto J, et al:Leptomeningeal metastasis from solid tumors:A diagnostic and therapeutic challenge. Neurol Sci 2015;36:117-23.
PubMed
72) Tsuchiya K, Katase S, Yoshino A, et al:FLAIR MR imaging for diagnosing intracranial meningeal carcinomatosis. AJR Am J Roentgenol 2001;176:1585-8.
PubMed
73) Enting RH:Leptomeningeal neoplasia:Epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res 2005;125:17-30.
PubMed
74) Glantz MJ, Cole BF, Glantz LK:Cerebrospinal fluid cytology in patients with cancer:Minimizing false-negative results. Cancer 1988;82:733-9.
 
75) Chamberlain M, Soffietti R, Raizer J, et al:Leptomeningeal metastasis:A response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014;16:1176-85.
PubMed
76) Boogerd W, van den Bent MJ, Koehler PJ, et al:The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer:A randomized study. Eur J Cancer 2004;40:2726-33.
PubMed
77) Zagouri F, Sergentanis TN, Bartsch R, et al:Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer:A systematic review and pooled analysis. Breast Cancer Res Treat 2013;139:13-22.
PubMed
78) Kumthhekar PU, Avram MJ, Lassman AB, et al:A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases:Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol 2023;25:557-65.
 
79) Kak M, Nanda R, Ramsdale EE, et al:Treatment of leptomeningeal carcinomatosis:Current challenges and future opportunities. J Clin Neurosci 2015;22:632-7.
PubMed
80) Taillibert S, Hildebrand J:Treatment of central nervous system metastases:Parenchymal, epidural, and leptomeningeal. Curr Opin Oncol 2006;18:637-43.
PubMed
81) Mehta M, Bradley K:Radiation therapy for leptomeningeal cancer. Cancer Treat Res 2005;125:147-58.
PubMed
82) Ballard P, Yates JW, Yang Z, et al:Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016;22:5130-40.
PubMed
83) Park S, Lee MH, Seong M, et al:A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 2020;31:1397-404.
PubMed
84) Yang JCH, Kim SW, Kim DW, et al:Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases:The BLOOM study. J Clin Oncol 2020;38:538-47.
PubMed
85) Lin NU, Borges V, Anders C, et al:Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38:2610-9.
 
86) Murthy RK, Loi S, Okines A, et al:Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020;382:597-609.
PubMed
87) Brastianos PK, Lee EQ, Cohen JV, et al:Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 2020;26:1280-4.
PubMed
88) Maillie L, Salgado LR, Lazarev S:A systematic review of craniospinal irradiation for leptomeningeal disease:Past, present, and future. Clin Transl Oncol 2021;23:2109-19.
 
89) Chang EL, Wefel JS, Hess KR, et al:Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus wholebrain irradiation:A randomised controlled trial. Lancet Oncol 2009;10:1037-44.
PubMed
90) Yang JT, Wijetunga NA, Pentsova E, et al:Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J Clin Oncol 2022;40:3858-67.
PubMed
91) Jung TY, Chung WK, Oh IJ:The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosurg 2014;119:80-3.
PubMed
92) Su YH, Chiang CL, Yang HC, et al:Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis. Acta Neurochir (Wien) 2022;164:459-67.
PubMed
93) Nigim F, Critchlow JF, Kasper EM:Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system:An analysis of 59 cases. Mol Clin Oncol 2015;3:1381-6.
PubMed
94) Omuro AMP, Lallana EC, Bilsky MH, et al:Ventriculoperitoneal shunt in patients with leptomeningeal metasta sis. Neurology 2005;64:1625-7.
 
95) Rahmathulla G, Marko NF, Weil RJ:Cerebral radiation necrosis:A review of the pathobiology, diagnosis and management considerations. J Clin Neurosci 2013;20:485-502.
PubMed
96) Greene-Schloesser D, Robbins ME, Peiffer AM, et al:Radiation-induced brain injury:A review. Front Oncol 2012;2:73-5.
PubMed
97) Shah R, Vattoth S, Jacob R, et al:Radiation necrosis in the brain:Imaging features and differentiation from tumor recurrence. Radiographics 2012;32:1343-59.
PubMed
98) Brandsma D, Stalpers L, Taal W, et al:Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-61.
PubMed
99) Levin VA, Bidaut L, Hou P, et al:Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011:79:1487-95.
PubMed
100) Scott BJ:Neuro-oncologic emergencies. Semin Neurol 2015;35:675-82.
PubMed
101) Armand JP, Ribrag V, Harrousseau JL, et al:Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 2007;3:213-24.
PubMed
102) Jo JT, Schiff D:Management of neuro-oncologic emergencies. Handb Clin Neurol 2017;141:715-41.
PubMed
103) Herzig RH, Hines JD, Herzig GP, et al:Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987;5:927-32.
PubMed
104) Stupp R, Mason WP, van den Bent MJ, et al:Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
PubMed
105) Arrieta VA, Dmello C, McGrail DJ, et al:Immune checkpoint blockade in glioblastoma:From tumor heterogeneity to personalized treatment. J Clin Invest 2023;133:e163447.
PubMed
106) Martins F, Sofiya L, Sykiotis GP, et al:Adverse effects of immune-checkpoint inhibitors:Epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80.
PubMed
107) Shord SS, Bressler LR, Tierney LA, et al:Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009;66:999-1013.
PubMed

第6章 血液腫瘍科の立場から

P.80 掲載の参考文献
1) Stucki A, Rivier AS, Gikic M, et al:Endothelial cell activation by myeloblasts:Molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001;97:2121-9.
PubMed
2) Rodgers R, Latif Z, Copland M:How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol 2012;158:155-64.
 
3) Garcia-Pagan JC, Valla DC:Primary Budd-Chiari syndrome. N Engl J Med 2023;388:1307-16.
PubMed
4) Iizuka K, Morishita S, Nishizaki Y, et al:von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol 2022;109:779-86.
PubMed
5) Taplitz RA, Kennedy EB, Bow EJ, et al:Outpatient management of fever and neutropenia in adults treated for malignancy:American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline update. J Clin Oncol 2018;36:1443-53.
 
6) Innes H, Lim SL, Hall A, et al:Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index:Feasibility and safety in routine clinical practice. Support Care Cancer 2008;16:485-91.
PubMed
7) Nachman RL, Rafii S:Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008;359:1261-70.
 
8) Menell JS, Cesarman GM, Jacovina AT, et al:Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994-1004.
PubMed
9) Sanz MA, Fenaux P, Tallman MS, et al:Management of acute promyelocytic leukemia:Updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133:1630-43.
 
10) Matsue K, Abe Y, Kitadate A, et al:Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood 2019;133:1257-9.
 
11) Fourney DR, Frangou EM, Ryken TC, et al:Spinal instability neoplastic score:An analysis of reliability and validity from the spine oncology study group. J Clin Oncol 2011;29:3072-7.
 
12) Fisher CG, Dipaola CP, Ryken TC, et al:A novel classification system for spinal instability in neoplastic disease:An evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine(Phila Pa 1976)2010;35:E1221-9.
 

第7章 泌尿器科の立場から

P.88 掲載の参考文献
1) 日本産婦人科医会:オンコロジーエマージェンシー(oncology emergency). 女性のがん;サポーティブケア. https://www.jaog.or.jp/note/12739/
 
2) 血尿診断ガイドライン編集委員会, 他(編):血尿診断ガイドライン2013. ライフサイエンス出版, 東京, 2013.
 
3) Woldu SL, Ng CK, Loo RK, et al:Evaluation of the New American Urological Association Guidelines risk classification for hematuria. J Urol 2021;205:1387-93.
 
4) Skinner DG, Colvin RB, Vermillion CD, et al:Diagnosis and management of renal cell carcinoma:A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
PubMed
5) 清野精康, 木村信吾, 竹田篤史, 他:S状結腸がん膀胱浸潤の難治性膀胱出血に対して鏡視下尿管皮膚瘻造設術を施行した1例. 岩手病医会誌 2018;58:50-4.
 
6) Kobayashi T, Kamoto T, Sugino Y, et al:High incidence of urinary bladder involvement in carcinomas of the sigmoid and rectum:A retrospective review of 580 patients with colorectal carcinoma. J Surg Oncol 2003;84:209-14.
PubMed
7) Smit SG, Heyns CF:Management of radiation cystitis. Nat Rev Urol 2010;7:206-14.
PubMed
8) 厚生労働省:重篤副作用疾患別対応マニュアル;出血性膀胱炎. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1n07-r03.pdf
 
9) 中田瑛浩, 矢口博理, 三條康典:膀胱タンポナーデの診断と治療. 泌尿器外科 1995;8:935-8.
Medical*Online
10) 松山奈有佳, 服部竜也, 河瀬健吾, 他:ステロイドが奏効した放射線性出血性膀胱炎の1例. 泌尿器外科 2019;32:73-5.
Medical*Online
11) 原口貴裕, 山崎隆文, 武市佳純, 他:放射線性出血性膀胱炎;ホルマリン綿片を用いた経尿道的治療法. 泌尿器科紀要 2007;53:585-7.
 
12) 牧野哲也, 細野智子, 田中智章, 他:出血性膀胱炎, 間質性膀胱炎に対する高気圧酸素療法. 泌尿器外科 2007;20:1475-8.
Medical*Online
13) 日本緩和医療学会緩和医療ガイドライン委員会(編):がん患者の泌尿器症状の緩和に関するガイドライン. 2016年版, 金原出版, 東京, 2016.
 
14) 堀夏樹, 鈴木正寛:泌尿器系のOncology Emergency. 癌と化学療法 2008;35:2321-5.
Medical*Online
15) 逢坂公人, 藤岡あずみ, 村岡研太郎, 他:尿路外悪性腫瘍に伴う水腎症に対する金属尿管ステントの使用成績及び排尿症状に関する検討. Jpn J Endourol 2019;32:185-9.
 
16) Liatsikos E, Kallidonis P, Kyriazis I, et al:Ureteral obstruction:Is the full metallic double-pigtail stent the way to go? Eur Urol 2010;57:480-6.
PubMed

第8章 がん免疫療法の立場から

P.94 掲載の参考文献
1) Postow MA:Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015;76-83.
PubMed
2) Dillard T, Yedinak CG, Alumkal J, et al:Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis:Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29-38.
PubMed
3) Yervoy(TM) (ipilimumab) Risk Evaluation and Mitigation Strategy (REMS). http://www.accessdata.fda.gov/drugsatfda_docs/rems/Yervoy_2012-02-16_Full.pdf
 
4) Yervoy(TM) (ipilimumab) prescribing information. http://packageinserts.bms.com/pi/pi_yervoy.pdf
 
5) OPDIVO(R) (nivolumab) prescribing information. revised 10/2016. http://packageinserts.bms.com/pi/pi_opdivo.pdf(accessed 2023-5-18).
 
6) KEYTRUDA(R) (pembrolizumab) prescribing information. revised 8/2016. http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
 
7) Coit DG, Thompson JA, Algazi A, et al:NCCN Guidelines insights:Melanoma, version 3. 2016. J Natl Compr Canc Netw 2016;14:945-58.
PubMed
8) Davies M:How checkpoint inhibitors are changing the treatment paradigm in solid tumors:What advanced practitioners in oncology need to know. J Adv Pract Oncol 2016;7:498-509.
 
9) Rubin KM:Managing immune-related adverse events to ipilimumab:A nurse's guide. Clin J Oncol Nurs 2012;16:E69-75.
 
10) Honma O, Watanabe C, Fukuchimoto H, et al:Verification of the usefulness of an assessment and risk control sheet that promotes management of cancer drug therapy. Front Pharmacol 2022;13:744916.
PubMed
11) Di Giacomo AM, Danielli R, Guidoboni M, et al:Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments:Clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009;58:1297-306.
PubMed
12) Park HJ, Kim KW, Pyo J, et al:Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors:A systematic review and meta-analysis. Radiology 2020;297:87-96.
PubMed
13) Sanmamed MF, Perez-Gracia JL, Schalper KA, et al:Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 2017;28:1988-95.
PubMed
14) Kubota Y, Yoshimura K, Hamada K, et al:Rare nivolumab-associated super hyper progressive disease in patients with advanced gastric cancer. In Vivo 2021;35:1865-75.
PubMed
15) Saada-Bouzid E, Defaucheux C, Karabajakian A, et al:Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.
PubMed
16) Takahashi Y, Sunakawa Y, Inoue E, et al:Real-world effectiveness of nivolumab in advanced gastric cancer:The DELIVER trial (JACCRO GC-08). Gastric Cancer 2022;25:235-44.
PubMed

第9章 緩和ケアの立場から

P.105 掲載の参考文献
1) Lynn J, Adamson DM:Living well at the end of life:Adapting health care to serious chronic illness in old age. RAND, Santa Monica, 2003, pp1-19.
 
2) World Health Organization (WHO):Palliative care. https://www.who.int/news-room/fact-sheets/detail/palliative-care
 
3) 厚生労働省:「人生会議」してみませんか. https://www.mhlw.go.jp/stf/newpage_02783.html
 
4) 松本禎久, 上原優子:緩和医療特論. 日本がん治療認定医機構教育委員会(編), がん治療認定医教育セミナーテキスト, 第15版, 日本がん治療認定医機構教育委員会, 東京, 2021, pp90-6.
 
5) 西智弘, 松本禎久, 森雅紀, 他(編):緩和ケアレジデントマニュアル. 第2版, 森田達也, 他(監), 医学書院, 東京, 2022.
 
6) American Psychiatric Association(編):DSM-5(R) 精神疾患の診断・統計マニュアル. 日本精神神経学会(監), 高橋三郎, 他(監訳), 医学書院, 東京, 2014.
 
7) 社会保険診療報酬支払基金:審査情報提供事例(薬剤);100番台 神経系及び感覚器官用医薬品. https://www.ssk.or.jp/shinryohoshu/teikyojirei/yakuzai/no100/index.html
 
8) 日本緩和医療学会(編):がん疼痛の薬物療法に関するガイドライン2020年版. 第3版, 金原出版, 東京, 2020.
 
9) Kim SC, Tse DM, Sham MMK, et al:Dyspnoea and other respiratory symptoms in palliative care. Oxford Textbook of Palliative Medicine, 5th ed, Oxford University Press, New York, 2015, pp421-34.
 
10) Ben-Aharon L, Gafter-Gvili A, Paul M, et al:Interventions for alleviating cancer-related dyspnea:A systematic review. J Clin Oncol 2008;26:2396-404.
 
11) Ripamonti C, Mercadante S, Groff L, et al:Role of octoreotide, scoporamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes:A prospective randomized trial. J Pain Symptom Manage 2000;19:23-34.
 
12) Feuer DJ, Broadley KE:Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000;2000:CD001219.
PubMed
13) Dasanu CA, Trikudanathan G, Bandyopadhyay T, et al:Tumor fever, paraneoplastic leukocytosis and necrotic liver metastases:A triad worth remembering. Conn Med 2010;74:389-91.
PubMed
14) Hui D, dos Santos R, Chisholm G, et al:Clinical signs of impending death in cancer patients. Oncologist 2014;19:681-7.
 
15) Morita T, Tsunoda J, Inoue S, et al:The palliative prognostic index:A scoring system for survival prediction of terminally ill cancer patients:Support Care Cancer 1999;7:128-33.
PubMed
16) Maltoni M, Nanni O, Pirovano M, et al:Successful validation of the palliative prognostic score in terminally ill cancer patients:Italian multicenter study group on palliative care. J Pain Symptom Manage 1999;17:240-7.
 
17) Glare P, Virik K, Jones M, et al:A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195-8.
 
18) 日本緩和医療学会ガイドライン統括委員会(編):がん患者の治療抵抗性の苦痛と鎮静に関する基本的な考え方の手引き. 2018年版, 金原出版, 東京, 2018.
 
19) Maeda I, Morita T, Yamaguchi T, et al:Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval):A propensity score-weighted analysis of a prospective cohort study. Lancet Oncol 2016;17:115-22.
 

第10章 救急医の立場から

P.118 掲載の参考文献
1) Hsu J, Donnelly JP, Moore JX, et al:National characteristics of emergency department visits by patients with cancer in the United States. Am J Emerg Med 2018;36:2038-43.
PubMed
2) Gould Rothberg BE, Quest TE, Yeung SJ, et al:Oncologic emergencies and urgencies:A comprehensive review. CA Cancer J Clin 2022;72:570-93.
PubMed
3) 国立がんセンター:がん情報サービス;がん統計. https://ganjoho.jp/reg_stat/index.html
 
4) Pelosof LC, Gerber DE:Paraneoplastic syndromes:An approach to diagnosis and treatment. Mayo Clin Proc 2010;85:838-54.
PubMed
5) 岩間信太郎, 有馬寛:低ナトリウム血症と内分泌疾患. 日内会誌 2020;109:705-11.
 
6) Ellison DH, Berl T:Clinical practice:The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72.
PubMed
7) Raftopoulos H:Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 2007;15:1341-7.
PubMed
8) 厚生労働科学研究費補助金難治性疾患等政策研究事業「間脳下垂体機能障害に関する調査研究」班(編):間脳下垂体機能障害の診断と治療の手引き(平成30年度改訂). 日内分泌会誌 2019;95(S. May):1-60.
 
9) Lumachi F, Brunello A, Roma A, et al:Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 2008;15:415-21.
PubMed
10) Ratcliffe WA, Hutchesson AC, Bundred NJ, et al:Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992;339:164-7.
PubMed
11) 福原傑:高カルシウム血症と腫瘍崩壊症候群. 日腎会誌 2017;59:598-605.
 
12) Goldner W:Cancer-related hypercalcemia. J Oncol Pract 2016;12:426-32.
PubMed
13) Stewart AF:Clinical practice:Hypercalcemia associated with cancer. N Engl J Med 2005;27;352:373-9.
 
14) Khan AA, Gurnani PK, Peksa GD, et al:Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy. Ann Pharmacother 2021;55:277-85.
PubMed
15) Fizazi K, Carducci M, Smith M, et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:A randomised, double-blind study. Lancet 2011;377:813-22.
PubMed
16) LeGrand SB, Leskuski D, Zama I:Narrative review:Furosemide for hypercalcemia:An unproven yet common practice. Ann Intern Med 2008;149:259-63.
PubMed
17) 犬塚貴:傍腫瘍性神経症候群-update. 臨床神経 2011;51:834-7.
 
18) Agnelli G, Becattini C, Meyer G, et al:Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607.
PubMed
19) Friedman T, Quencer KB, Kishore SA, et al:Malignant venous obstruction:Superior vena cava syndrome and beyond. Semin Intervent Radiol 2017;34:398-408.
PubMed
20) Kumar A, Weber MH, Gokaslan Z, et al:Metastatic spinal cord compression and steroid treatment:A systematic review. Clin Spine Surg 2017;30:156-63.
PubMed
21) Brown PD, Jaeckle K, Ballman KV, et al:Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases:A randomized clinical trial. JAMA 2016;316:401-9.
PubMed
22) Prabhakar H, Singh GP, Anand V, et al:Mannitol versus hypertonic saline for brain relaxation in patients undergoing craniotomy. Cochrane Database Syst Rev 2014;2014:CD010026.
PubMed
23) Kong X, Guan J, Yang Y, et al:A meta-analysis:Do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures? Clin Neurol Neurosurg 2015;134:98-103.
 
24) Varadharajan K, Mathew R, Odutoye B, et al:Use of tracheal stenting in the palliation of anaplastic thyroid carcinoma:Tertiary centre experience. J Laryngol Otol 2015;129:568-71.
PubMed
25) Maisch B, Seferovic PM, Ristic AD, et al:Guidelines on the diagnosis and management of pericardial diseases executive summary. Eur Heart J 2004;25:587-610.
PubMed
26) Cairo MS, Coiffier B, Reiter A, et al:Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases:An expert TLS panel consensus. Br J Haematol 2010;149:578-86.
PubMed
27) 日本臨床腫瘍学会(編):腫瘍崩壊症候群 (TLS) 診療ガイダンス. 金原出版, 東京, 2013.
 
28) 日本臨床腫瘍学会(編):発熱性好中球減少症 (FN) 治療ガイドライン;がん薬物療法時の感染対策. 改訂第2版, 南江堂, 東京, 2017.
 
29) Klastersky J, Paesmans M:The Multinational Association for Supportive Care in Cancer (MASCC) risk index score:10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013;21:1487-95.
PubMed
30) Al Beihany A, Al Omar H, Sahovic E, et al:Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 2008;41:287-91.
 
31) Ho VT, Revta C, Richardson PG:Hepatic veno-occlusive disease after hematopoietic stem cell transplantation:Update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008;41:229-37.
PubMed
32) Riondino S, Del Monte G, Fratangeli F, et al:Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer. Cardiovasc Hematol Agents Med Chem 2017;15:3-16.
PubMed
33) 日本臨床腫瘍学会(編):がん免疫療法ガイドライン. 第3版, 金原出版, 東京, 2023.
 
34) American Society of Clinical Oncology (ASCO(R)):Guidelines & Measures Annual Report. 2022. https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/practice-patients/documents/2022-annual-report-full.pdf
 
35) Lee DW, Gardner R, Porter DL, et al:Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.
PubMed
36) Santomasso B, Bachier C, Westin J, et al:The other side of CAR T-cell therapy:Cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book 2019;39:433-44.
PubMed
37) Coyne CJ, Reyes-Gibby CC, Durham DD, et al:Cancer pain management in the emergency department:A multicenter prospective observational trial of the Comprehensive Oncologic Emergencies Research Network (CONCERN). Support Care Cancer 2021;29:4543-53.
 
38) Glare PA, Davies PS, Finlay E, et al:Pain in cancer survivors. J Clin Oncol 2014;32:1739-47.
PubMed
39) Patel PM, Goodman LF, Knepel SA, et al:Evaluation of emergency department management of opioid-tolerant cancer patients with acute pain. J Pain Symptom Manage 2017;54:501-7.
PubMed
40) McDermott CL, Fedorenko C, Kreizenbeck K, et al:End-of-life services among patients with cancer:Evidence from cancer registry records linked with commercial health insurance claims. J Oncol Pract 2017;13:e889-99.
 

第11章 在宅医療の立場から

P.130 掲載の参考文献
1) 内閣府:コラム1「高齢社会」「高齢化社会」とは?平成18年版高齢社会白書(全体版), 2006. https://www8.cao.go.jp/kourei/whitepaper/w-2006/zenbun/html/i1111000.html
 
2) 内閣府:高齢化の現状と将来像. 令和3年度 高齢化の状況及び高齢社会対策の実施状況, pp2-6. https://www8.cao.go.jp/kourei/whitepaper/w-2022/zenbun/pdf/1s1s_01.pdf
 
3) 国立社会保障・人口問題研究所:日本の将来推計人口(平成29年推計). https://www.ipss.go.jp/pp-zenkoku/j/zenkoku2017/pp_zenkoku2017.asp
 
4) 内閣府:高齢化の国際的動向. 令和元年度 高齢化の状況及び高齢社会対策の実施状況. https://www8.cao.go.jp/kourei/whitepaper/w-2020/html/zenbun/s1_1_2.html
 
5) 厚生労働省:地域包括ケアシステム. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hukushi_kaigo/kaigo_koureisha/chiiki-houkatsu/
 
6) 厚生労働省:第2回在宅医療及び医療・介護連携に関するワーキンググループ;参考資料. 令和4年3月9日. https://www.mhlw.go.jp/content/10800000/000909712.pdf
 
7) 小豆畑丈夫:在宅医療の真実. 光文社, 東京, 2021.
 
8) 日経BP:日経ヘルスケア. 2022年8月号, no. 394.
 
9) Todd KH, Thomas CR Jr, Alagappan K:Oncologic Emergency Medicine:Pricciples and Practice. Springer, 2016.
 
10) 小豆畑丈夫:Oncologic emergency. 一般社団法人日本Acute Care Surgery学会テキスト作成小委員会(編), Acute Care Surgey 認定外科医テキスト, へるす出版, 東京, 2021, pp271-8.
 
11) がん研有明病院:救急部. https://www.jfcr.or.jp/hospital/department/clinic/central/emergency/feature.html
 
12) 総務省消防庁:平成15年中 救急・救助の概要(速報版). https://www.fdma.go.jp/publication/rescue/items/kkkg_15_gaiyo.pdf
 
13) 総務省消防庁:平成18年版 救急救助の現況. https://www.fdma.go.jp/publication/rescue/items/h18_kyukyu_kyujo.pdf
 
14) 総務省消防庁:平成23年版 救急救助の現況. https://www.fdma.go.jp/publication/rescue/items/02_mokuji.pdf
 
15) 総務省消防庁:平成28年版 救急救助の現況. https://www.fdma.go.jp/publication/rescue/post6.html
 
16) 総務省消防庁:令和4年版 救急救助の現況. https://www.fdma.go.jp/publication/rescue/post-4.html
 
17) 中村和裕, 小豆畑丈夫, 小林美香, 他:COVID-19感染拡大による, 在宅-病院連携の変化と問題点. 日在宅救急医会誌 2022;6:34-6.
Medical*Online
18) 会田薫子:長寿時代の医療・ケア;エンドオブライフの論理と倫理. 筑摩書房, 東京, 2019.
 
19) 宇都宮啓:平成26年度診療報酬改定の概要. https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000039378.pdf
 
20) 一般社団法人日本在宅救急医学会ホームページ. http://zaitakukyukyu.com/index.html
 
21) 小豆畑丈夫:日本在宅救急医学会の道のり. https://note.com/tazuhata1969/m/m80335fc003f3
 
22) 小豆畑丈夫, 中村和裕, 河野大輔, 他:新型コロナウイルス感染症拡大が, 一般医療機関(在宅医療および一般急性期医療)に与えた影響. 日在宅救急医会誌 2022:6:30-3.
Medical*Online

第12章 麻酔科の立場から

P.139 掲載の参考文献
1) Buddeberg BS, Seeberger MD:Anesthesia and oncology:Friend or foe? Front Oncol 2022;12:802210.
PubMed
2) Keane E, Nestor CC:Implications of anaesthesia on cancer surgery. ATOTW 487, 2022. https://resources.wfsahq.org/wp-content/uploads/atow-487-00.pdf
 
3) Tomura S, de Rivero Vaccari JP, Keane RW, et al:Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury. J Cereb Blood Flow Metab 2012;32:1939-47.
PubMed
4) Wigmore TJ, Mohammed K, Jhanji S:Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery:A retrospective analysis. Anesthesiology 2016;124:69-79.
PubMed
5) Jun IJ, Jo JY, Kim JI, et al:Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery:A retrospective observational study. Sci Rep 2017;7:14020.
PubMed
6) Kim MH, Kim DW, Kim JH, et al:Does the type of anesthesia really affect the recurrence-free survival after breast cancer surgery? Oncotarget 2017;8:90477-87.
PubMed
7) Zheng X, Wang Y, Dong L, et al:Effects of propofol-based total intravenous anesthesia on gastric cancer:A retrospective study. Onco Targets Ther 2018;11:1141-8.
 
8) Wu ZF, Lee MS, Wong CS, et al:Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in colon cancer surgery. Anesthesiology 2018;129:932-41.
PubMed
9) Huang YH, Lee MS, Lou YS, et al:Propofol-based total intravenous anesthesia did not improve survival compared to desflurane anesthesia in breast cancer surgery. PLoS One 2019;14:e0224728.
PubMed
10) Oh TK, Kim HH, Jeon YT:Retrospective analysis of 1-year mortality after gastric cancer surgery:Total intravenous anesthesia versus volatile anesthesia. Acta Anaesthesiol Scand 2019;63:1169-77.
PubMed
11) Enlund M, Berglund A, Ahlstrand R, et al:Survival after primary breast cancer surgery following propofol or sevoflurane general anesthesia:A retrospective, multicenter, database analysis of 6305 Swedish patients. Acta Anaesthesiol Scand 2020;64:1048-54.
 
12) Hasselager RP, Hallas J, Gogenur I:Inhalation or total intravenous anaesthesia and recurrence after colorectal cancer surgery:A propensity score matched Danish registry-based study. Br J Anaesth 2021;126:921-30.
 
13) Miao L, Lv X, Huang C, et al:Long-term oncological outcomes after oral cancer surgery using propofol-based total intravenous anesthesia versus sevoflurane-based inhalation anesthesia:A retrospective cohort study. PLoS One 2022;17:e0268473.
 
14) Yap A, Lopez-Olivo MA, Dubowitz J, et al:Anesthetic technique and cancer outcomes:A meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth 2019;66:546-61.
PubMed
15) Janku F, Johnson LK, Karp DD, et al:Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol 2016;27:2032-8.
PubMed
16) Wall T, Sherwin A, Ma D, et al:Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes:A narrative review. Br J Anaesth 2019;123:135-50.
PubMed
17) Cronin-Fenton DP, Heide-Jorgensen U, Ahern TP, et al:Opioids and breast cancer recurrence:A Danish population-based cohort study. Cancer 2015;121:3507-14.
PubMed
18) Sherwin A, Wall T, Buggy DJ:Anaesthesia and cancer recurrence. 2022. https://www.uptodate.com/contents/anesthesia-and-cancer-recurrence#H2875951382
 
19) Piazuelo E, Lanas A:NSAIDS and gastrointestinal cancer. Prostaglandins Other Lipid Mediat 2015;120:91-6.
PubMed
20) Veitonmaki T, Tammela TL, Auvinen A, et al:Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013;49:938-45.
 
21) Connolly JG, Tan KS, Mastrogiacomo B, et al:Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br J Anaesth 2021;127:75-84.
PubMed
22) Cata JP, Singh V, Lee BM, et al:Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol 2017;33:317-23.
PubMed
23) Hurth KP, Jaworski A, Thomas KB, et al:The reemergence of ketamine for treatment in critically ill adults. Crit Care Med 2020;48:899-911.
PubMed
24) Melamed R, Bar-Yosef S, Shakhar G, et al:Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol:Mediating mechanisms and prophylactic measures. Anesth Analg 2003;97:1331-9.
 
25) Amato A, Pescatori M:Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;2006:CD005033.
PubMed
26) Li SL, Ye Y, Yuan XH:Association between allogeneic or autologous blood transfusion and survival in patients after radical prostatectomy:A systematic review and meta-analysis. PLoS One 2017;12:e0171081.
PubMed
27) Agnes A, Lirosi MC, Panunzi S, et al:The prognostic role of perioperative allogeneic blood transfusions in gastric cancer patients undergoing curative resection:A systematic review and meta-analysis of non-randomized, adjusted studies. Eur J Surg Oncol 2018;44:404-19.
PubMed
28) Glasner A, Avraham R, Rosenne E, et al:Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010;184:2449-57.
 
29) Choi CH, Song T, Kim TH, et al:Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol 2014;140:1179-88.
PubMed
30) Yap A, Lopez-Olivo MA, Dubowitz J, et al:Effect of beta-blockers on cancer recurrence and survival:A meta-analysis of epidemiological and perioperative studies. Br J Anaesth 2018;121:45-57.
PubMed
31) Gould Rothberg BE, Quest TE, Yeung SJ, et al:Oncologic emergencies and urgencies:A comprehensive review. CA Cancer J Clin 2022;72:570-93.
PubMed
32) Urban MK:Muscle Diseases. In Anesthesia and Uncommon Disease. 5th. ed by Fleisher LA, Elsevier, Amsterdam, 2006, pp303-25.
 
33) Nagy-Mignotte H, Shestaeva O, Vignoud L, et al:Prognostic impact of paraneoplastic Cushing's syndrome in small-cell lung cancer. J Thorac Oncol 2014;9:497-505.
PubMed
34) Weingarten TN, Araka CN, Mogensen ME, et al:Lambert-Eaton myasthenic syndrome during anesthesia:A report of 37 patients. J Clin Anesth 2014;26:648-53.
PubMed
35) Chaudhary K, Gupta A, Wadhawan S, et al:Anesthetic management of superior vena cava syndrome due to anterior mediastinal mass. J Anaesthesiol Clin Pharmacol 2012;28:242-6.
 
36) Andrabi T, French KE, Qazilbash MH:New cancer therapies:Implications for the perioperative period. Curr Anesthesiol Rep 2018;8:362-7.
PubMed
37) Porta-Sanchez A, Gilbert C, Spears D, et al:Incidence, diagnosis, and management of QT prolongation induced by cancer therapies:A systematic review. J Am Heart Assoc 2017;6:e007724.
PubMed

書評

最近チェックした商品履歴

Loading...